Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA: ALI HEALTH (00241.HK) 1HFY26 Results Slightly Beat
Recommend 8 Positive 6 Negative 4 |
||||
|
||||
|
CLSA released a report covering ALI HEALTH (00241.HK), of which 1HFY26 results slightly beat, with both revenue and profit advancing, thanks to solid first-party sales, although third-party platform missed expectation. Adjusted net profit hiked 39% YoY, with GM of 8.1%, ahead of the broker's estimate of 7.7%. ALI HEALTH maintained its FY2026 guidance, projecting revenue growth of 10-15%, implying a 13% YoY growth rate needed for 2H, and profit growth of 20-30%, implying a 21% YoY growth rate needed for 2H. The broker forecast that sales of originator drugs should sustain strong growth in the coming quarters, while sales of healthcare devices may face uncertainties as the impact of the trade-in program gradually fades. The rating on ALI HEALTH was Outperform with a target price of HKD6.5. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
